Live Long and Well with Dr. Bobby

Send us Fan Mail
Visit my website

Bold claims make great headlines; clear evidence makes better habits. We take a hard look at the widely shared study suggesting two to three cups of coffee cut dementia risk by 20 percent and unpack what those numbers really mean for your brain and your daily routine.

First, we break down the Harvard JAMA research: massive cohorts of nurses and physicians, decades of follow-up, and self-reported diet data that carry real strengths and built-in limits. We explore why observational studies can’t prove causation, how confounders like sleep, exercise, and income can bend results, and why tea showing similar benefits while decaf shows none points to caffeine yet refuses a tidy explanation. Then we translate relative risk into absolute terms to show how a big percentage drop can still be a small difference in real life, and we discuss the publication bias that comes from testing many hypotheses and promoting only the eye-catching hits.

Next, we turn to trials where the science gets sharper. The CRAVE study randomized coffee days in healthy adults with continuous heart monitoring and found no rise in atrial abnormalities that lead to atrial fibrillation, though there was a bump in benign PVCs. For those with a history of AF, the DCAF trial offers a surprise: participants who kept drinking coffee had almost half the recurrence rate compared with those who quit, suggesting caffeine didn’t worsen outcomes and might even help. The message for most people is reassuring—coffee isn’t the arrhythmia trigger it’s often made out to be.

Our bottom line is practical and personal. If coffee fits your life and doesn’t wreck your sleep, enjoy one or two cups without expecting miracles. Protect your rest first, because sleep debt is a far clearer risk to cognition than a second espresso is a remedy. Stay curious, ask how a study was designed, and look for consistent results across methods before changing routines. If you learned something helpful, tap follow, share this episode with a friend who loves their morning brew, and leave a quick review to help others find the show.

Send a text
You read everywhere that you “should” cut salt—especially if your blood pressure is up. But salt also makes food enjoyable. In this episode, I walk through the human evidence (not animal studies) and frame salt as a risk–benefit tradeoff: when does sodium meaningfully matter, for whom, and how can you test your sensitivity?
Big questions we answer
If you have high blood pressure: does lowering salt always help?
If your BP is normal but you have heart/kidney risk: does salt matter?
If you’re basically healthy: how worried should you be?
Key takeaways
Sodium is essential (nerves, muscles, fluid balance)—the issue is dose and individual response.
Most sodium comes from packaged/restaurant foods (not your salt shaker).
Salt restriction lowers BP, but the average effect is modest compared with typical BP meds (context matters).
Salt sensitivity varies: roughly ~30% of healthy people and ~40–50% of people with hypertension may be “salt-sensitive” (with higher rates in older adults, women, and some ancestry groups).
If you’re salt-sensitive—especially with hypertension—being mindful of sodium is likely worth it. If you’re not, the “must be low-salt for everyone” story is less clear.
Practical: Do an N-of-1 salt sensitivity test
Measure home BP daily (or a few times/day) for a week
Go lower-sodium for 1–2+ weeks (at least within guidelines, possibly lower)
Track BP change
Add salt back and watch what happens
Optional: repeat the low-salt phase for confirmation
 If BP shifts meaningfully (often ~3–5 mmHg+), you may be salt-sensitive.
Food reality check (why sodium adds up fast)
~10% of a 2,300 mg/day sodium “budget”: 2 slices bread, 1 Tbsp ketchup, or a pinch of salt
~1/3: 1 cup canned soup, 1 slice pizza, or a Big Mac
~1/2: frozen lasagna, a few deli slices, or a 6” cold-cut sub
 Cooking mostly from whole foods makes staying lower-sodium much easier.
Studies & resources mentioned (links embedded)
CDC hypertension awareness/treatment/control stats: https://www.cdc.gov/nchs/products/databriefs/db511.htm

Hypertension outcomes review (risk of events/death): https://pmc.ncbi.nlm.nih.gov/articles/PMC8292050/

Population sodium/BP overview (JACC): https://www.jacc.org/doi/10.1016/j.jacc.2019.11.055

DASH-Sodium trial (NEJM): https://www.nejm.org/doi/full/10.1056/NEJM200101043440101

Sodium restriction meta-analysis (BP/outcomes): https://pmc.ncbi.nlm.nih.gov/articles/PMC12624901/

Salt sensitivity overview (AHA/Hypertension): https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.123.17959

Heart failure trials/meta (salt restriction): https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.122.009879

Salt substitute trial (NEJM): https://www.nejm.org/doi/full/10.1056/NEJMoa2105675

Call to action
Are you going to run your own N-of-1 salt test? If you do, I’d love to hear what you learn.
Reminder: I’m an educational resource, no

Send a text
Can you predict when “bad things” will happen to your health—and more importantly, can you do anything about it? In this episode, I break down which prediction tools actually help you live long and well (because you can act on them), and which ones are mostly expensive fortune-telling. Joined by cardiologist Dr. Anthony Pearson (author of The Skeptical Cardiologist), we dig into heart-risk calculators, dementia genetics, and why biological age clocks aren’t ready for prime time.
Guest: Dr. Anthony Pearson, cardiologist and writer of The Skeptical Cardiologist (Substack)
Key topics & takeaways
Why “prediction” only matters if it changes what you do—and improves real outcomes.
A red flag to watch for: is the person promoting the tool also selling the test, supplements, or “hacks” to fix it?
A sobering reality check: even doctors’ YouTube claims often lack strong evidence (and the least evidence-based content gets more views).
Heart disease risk equations: the gold standard in prediction because we can reduce risk factors (BP, LDL/ApoB, smoking, diabetes) and clinical trials show outcomes improve.
But even good tools miss people: a study of <65-year-olds who had heart attacks found many were labeled “low risk” beforehand.
Dementia genetics (ApoE): ApoE4 raises risk (especially E4/E4), but it’s not destiny. You can’t change genes—so the value of testing depends on whether it motivates healthy behaviors or creates anxiety.
Biological age clocks: fascinating research, messy consumer product. Different tests disagree, repeat testing can vary wildly, and most importantly—no proof that “lowering” a clock improves health outcomes or longevity. My advice: save your money (for now).
Links & resources mentioned
Wall Street Journal: longevity calculators for retirement planning: https://www.wsj.com/personal-finance/retirement/i-tried-answering-a-big-unknown-in-retirement-planning-how-long-will-i-live-9ef468df

Evidence behind doctors’ YouTube claims (JAMA Network Open): https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2844038

Example of strong claims vs broader evidence debate (Substack): https://substack.com/@drjasonfung1/p-182794806

Framingham Heart Study overview (risk factors history): https://pmc.ncbi.nlm.nih.gov/articles/PMC4159698/

Heart-attack patients labeled “low risk” by calculators (JACC Advances): https://www.jacc.org/doi/10.1016/j.jacadv.2025.102361

Biological age clock reliability issues (comparison across clocks): https://pmc.ncbi.nlm.nih.gov/articles/PMC9586209/

Call to action
If you found this useful, please share the episode with a friend and leave a quick review on Apple Podcasts or Spotify. Want my newsletter on practical, evidence-supported ways to improve longevity? Visit drbobbylivelongandwell.com.
And don’t forget to vote on what we should call this community: N of One Nation, Outcome Optimizers, Health Warriors, or something better.

Send a text

Send a text
A medicine that quiets food noise, trims 15 to 20 percent of body weight, and even lowers the risk of heart events sounds like a fantasy—until you meet GLP-1 drugs. We dig into what makes semaglutide and tirzepatide so different, how they rewire satiety signals, and why their impact extends beyond the scale to blood sugar, blood pressure, and cardiovascular outcomes. Along the way, we get candid about the trade-offs: GI side effects, lean mass loss, and the reality that stopping often means regaining much of the weight.

To go deeper, we’re joined by Dr. David Rind, chief medical officer at the Institute for Clinical and Economic Review (ICER), to decode how “value” gets measured in health care. Together we explore how these medications can be a strong value for individuals at today’s negotiated prices, yet still strain the entire system when millions qualify. You’ll hear why real-world discontinuation is high, why strength training and adequate protein are non-negotiable, and how benefits like fewer heart attacks, fewer joint surgeries, and improved quality of life factor into the equation.

We also tackle the hard question: how do we pay for a breakthrough at population scale without crowding out everything else? From Netflix-style subscription models and dedicated funding to competitive pricing and rethinking our hyperpalatable food environment, we outline pragmatic paths that could expand access while protecting budgets. If you’ve wondered whether GLP-1s are miracle drugs or money pits, this conversation offers a grounded, evidence-based guide to the science, the economics, and the choices ahead.

Enjoyed the show? Follow, share with a friend, and leave a quick review so more people can find it. Have thoughts or questions we should cover next? Send them our way and join the conversation.